The EDC3 Knockout MES-OV Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population with targeted disruption of the EDC3 gene, providing a loss-of-function model to investigate mRNA decapping and post-transcriptional regulation. The polyclonal format captures broad editing heterogeneity, avoiding clonal bias while enabling robust representation of CRISPR-induced edits across the cell population.
The MES-OV host cell line, derived from human ovarian adenocarcinoma, models high-grade serous ovarian carcinoma (HGSOC) with epithelial morphology and tumorigenic capacity. This cell system offers a relevant platform for studying ovarian cancer biology, drug response, and metastatic behavior, retaining molecular features typical of aggressive HGSOC.
EDC3 (Enhancer of mRNA Decapping 3) functions as a scaffold in the 5??-to-3?? mRNA decay pathway, enhancing decapping by bridging DCP2 with DCP1A and recruiting factors such as DDX6 and the LSM1-7 complex. Its activity is controlled upstream by mTOR and MAPK signaling, stress stimuli, and miRNAs. EDC3-mediated decay targets short-lived oncogenic mRNAs including MYC and CCND1; loss of EDC3 leads to transcript stabilization, disrupting normal gene expression.
In ovarian cancer, dysregulated mRNA decapping may promote malignant phenotypes. EDC3 knockout in MES-OV cells enables dissection of how impaired P-body dynamics and mRNA stabilization affect HGSOC proliferation, survival, and drug sensitivity, potentially revealing RNA turnover?Cdependent vulnerabilities.
These cells are suitable for diverse experimental workflows, including actinomycin D chase assays for global mRNA stability, RT-qPCR quantification of target transcripts, and immunofluorescence visualization of P-body components such as DDX6. Co-immunoprecipitation and western blotting can characterize decapping complex alterations, while polysome profiling, reporter gene assays, and RNA immunoprecipitation offer deeper mechanistic insight. For further details or technical support, please contact Ascent Research.
